U.S. Prescribing Information for Thyrogen Revised to Include Use of Wider Range of Radioiodine in Patients

Revised label will facilitate use of Thyrogen to greater number of patients for postoperative thyroid remnant ablation, March 27, 2014

CAMBRIDGE, Mass. – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the Food and Drug Administration (FDA) approved revised prescribing information for the use of Thyrogen® (thyrotropin alfa for injection) to widen the dose range of radioiodine (RAI) when used for thyroid remnant ablation. Read More…

THYROGEN® Highlights of Prescribing Information (PDF File, 666KB)

Share


Comments are closed.